- Home
- DYN vs INVA Comparison
DYN vs INVA Comparison
Compare DYN & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYN
- INVA
- Stock Information
- Founded
- DYN 1984
- INVA 1996
- Country
- DYN United States
- INVA United States
- Employees
- DYN N/A
- INVA N/A
- Industry
- DYN Medicinal Chemicals and Botanical Products
- INVA Biotechnology: Pharmaceutical Preparations
- Sector
- DYN Health Care
- INVA Health Care
- Exchange
- DYN Nasdaq
- INVA Nasdaq
- Market Cap
- DYN 1.4B
- INVA 1.2B
- IPO Year
- DYN 2020
- INVA 2004
- Fundamental
- Price
- DYN $12.50
- INVA $20.86
- Analyst Decision
- DYN Strong Buy
- INVA Strong Buy
- Analyst Count
- DYN 15
- INVA 4
- Target Price
- DYN $36.00
- INVA $40.25
- AVG Volume (30 Days)
- DYN 3.0M
- INVA 798.1K
- Earning Date
- DYN 07-28-2025
- INVA 08-06-2025
- Dividend Yield
- DYN N/A
- INVA N/A
- EPS Growth
- DYN N/A
- INVA N/A
- EPS
- DYN N/A
- INVA 0.53
- Revenue
- DYN N/A
- INVA $370,229,000.00
- Revenue This Year
- DYN N/A
- INVA $4.32
- Revenue Next Year
- DYN N/A
- INVA $9.24
- P/E Ratio
- DYN N/A
- INVA $39.15
- Revenue Growth
- DYN N/A
- INVA 12.02
- 52 Week Low
- DYN $6.36
- INVA $16.67
- 52 Week High
- DYN $47.45
- INVA $22.00
- Technical
- Relative Strength Index (RSI)
- DYN 70.49
- INVA 67.67
- Support Level
- DYN $10.78
- INVA $17.89
- Resistance Level
- DYN $12.59
- INVA $18.97
- Average True Range (ATR)
- DYN 0.82
- INVA 0.51
- MACD
- DYN 0.31
- INVA 0.29
- Stochastic Oscillator
- DYN 78.35
- INVA 99.29
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.